#$%^&*AU2020101858A420201008.pdf#####ABSTRACT The invention provides an application of a combination of medical device and labeling reagent in precision medical treatment of anti-myeloma. The medical device is an atmospheric pressure cold plasma treatment device. The labelling reagent is used for labelling CD95 target (preferably CD95 monoclonal antibody coupled with metal nanoparticles) and guiding the atmospheric pressure cold plasma to specifically gather on the CD95 target to attack, thus causing the selective death of tumor cells. The invention defines that the target of atmospheric pressure cold plasma inducing tumor cell death is CD95, through which the function of preferentially attacking tumor cells can be realized； in particular, monoclonal antibodies can be fixed on the CD95 protein of cells according to the specific binding of antigen and antibody, and metal nanoparticles will preferentially attract the attack of plasma, which leads to target cell death.
